KR102768101B1 - 유전자 변형된 비-인간 동물 및 그것의 사용 방법 - Google Patents
유전자 변형된 비-인간 동물 및 그것의 사용 방법 Download PDFInfo
- Publication number
- KR102768101B1 KR102768101B1 KR1020247008928A KR20247008928A KR102768101B1 KR 102768101 B1 KR102768101 B1 KR 102768101B1 KR 1020247008928 A KR1020247008928 A KR 1020247008928A KR 20247008928 A KR20247008928 A KR 20247008928A KR 102768101 B1 KR102768101 B1 KR 102768101B1
- Authority
- KR
- South Korea
- Prior art keywords
- human
- cells
- cell
- nucleic acid
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 436
- 238000000034 method Methods 0.000 title abstract description 107
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 171
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 147
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 147
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 61
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 57
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract description 47
- 102000052611 human IL6 Human genes 0.000 claims abstract description 47
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 44
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract description 42
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims abstract description 21
- 102000046157 human CSF2 Human genes 0.000 claims abstract description 20
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims abstract description 19
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims abstract description 19
- 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 claims abstract description 19
- 102000055276 human IL3 Human genes 0.000 claims abstract description 19
- 102000053400 human TPO Human genes 0.000 claims abstract description 19
- 241000283984 Rodentia Species 0.000 claims description 38
- 101100193633 Danio rerio rag2 gene Proteins 0.000 claims description 35
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 claims description 35
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 24
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 102000000646 Interleukin-3 Human genes 0.000 claims description 23
- 108010002386 Interleukin-3 Proteins 0.000 claims description 23
- 101710113649 Thyroid peroxidase Proteins 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 8
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract description 142
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 36
- 201000010099 disease Diseases 0.000 abstract description 30
- 101150036449 SIRPA gene Proteins 0.000 abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 15
- 230000003915 cell function Effects 0.000 abstract description 13
- 230000011712 cell development Effects 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 284
- 241000699670 Mus sp. Species 0.000 description 137
- 241001465754 Metazoa Species 0.000 description 134
- 108090000765 processed proteins & peptides Proteins 0.000 description 76
- 241000699666 Mus <mouse, genus> Species 0.000 description 70
- 108090000623 proteins and genes Proteins 0.000 description 70
- 239000003795 chemical substances by application Substances 0.000 description 67
- 206010035226 Plasma cell myeloma Diseases 0.000 description 66
- 102000004196 processed proteins & peptides Human genes 0.000 description 57
- 229940100601 interleukin-6 Drugs 0.000 description 54
- 229920001184 polypeptide Polymers 0.000 description 52
- 238000002054 transplantation Methods 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 40
- 210000003719 b-lymphocyte Anatomy 0.000 description 39
- 229940024606 amino acid Drugs 0.000 description 36
- 201000000050 myeloid neoplasm Diseases 0.000 description 36
- 125000003729 nucleotide group Chemical group 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 36
- 230000014509 gene expression Effects 0.000 description 35
- 239000000203 mixture Substances 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 35
- 206010028980 Neoplasm Diseases 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 34
- 239000002773 nucleotide Substances 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 30
- 208000034578 Multiple myelomas Diseases 0.000 description 30
- 238000001727 in vivo Methods 0.000 description 28
- 201000011510 cancer Diseases 0.000 description 27
- 108091033319 polynucleotide Proteins 0.000 description 27
- 102000040430 polynucleotide Human genes 0.000 description 27
- 239000002157 polynucleotide Substances 0.000 description 27
- 210000001185 bone marrow Anatomy 0.000 description 25
- 102000003839 Human Proteins Human genes 0.000 description 22
- 108090000144 Human Proteins Proteins 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 210000000988 bone and bone Anatomy 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 18
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 230000035772 mutation Effects 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 102100034195 Thrombopoietin Human genes 0.000 description 17
- 210000005260 human cell Anatomy 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- -1 aliphatic amino acids Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 101150101999 IL6 gene Proteins 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 13
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 210000000689 upper leg Anatomy 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 210000000628 antibody-producing cell Anatomy 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000003394 haemopoietic effect Effects 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 101100286713 Homo sapiens IL6 gene Proteins 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 9
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 230000001605 fetal effect Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 9
- 210000000287 oocyte Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000008499 blood brain barrier function Effects 0.000 description 8
- 210000001218 blood-brain barrier Anatomy 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 102100027207 CD27 antigen Human genes 0.000 description 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 7
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 7
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 7
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 7
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000000066 myeloid cell Anatomy 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 210000004180 plasmocyte Anatomy 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 101710091045 Envelope protein Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 101710188315 Protein X Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 101100069853 Caenorhabditis elegans hil-3 gene Proteins 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 206010064571 Gene mutation Diseases 0.000 description 5
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 230000011132 hemopoiesis Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000005170 neoplastic cell Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 231100000167 toxic agent Toxicity 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 4
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 4
- 101150025117 IL3 gene Proteins 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 241000699729 Muridae Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 101100286719 Mus musculus Il6 gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 4
- 101150077103 TPO gene Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 244000052637 human pathogen Species 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 3
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 3
- 102000001183 RAG-1 Human genes 0.000 description 3
- 108060006897 RAG1 Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000021120 animal protein Nutrition 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 210000002769 b effector cell Anatomy 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 210000000777 hematopoietic system Anatomy 0.000 description 3
- 238000011577 humanized mouse model Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 3
- 229940002005 zometa Drugs 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000121210 Sigmodontinae Species 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108010093528 Wiskott Aldrich Syndrome protein Proteins 0.000 description 2
- 102100023034 Wiskott-Aldrich syndrome protein Human genes 0.000 description 2
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 101150027964 ada gene Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 238000013425 morphometry Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000000113 radiomimetic effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000031998 transcytosis Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229940099039 velcade Drugs 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- BXRLWGXPSRYJDZ-VKHMYHEASA-N 3-cyano-L-alanine Chemical compound OC(=O)[C@@H](N)CC#N BXRLWGXPSRYJDZ-VKHMYHEASA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 101100485276 Arabidopsis thaliana XPO1 gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000398949 Calomyscidae Species 0.000 description 1
- 241000700193 Calomyscus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003727 Caveolin 1 Human genes 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 102000010567 DNA Polymerase II Human genes 0.000 description 1
- 108010063113 DNA Polymerase II Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241001095404 Dipodoidea Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000005289 Eukaryotic Initiation Factor-4A Human genes 0.000 description 1
- 108010056472 Eukaryotic Initiation Factor-4A Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001416537 Gliridae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- 101100340751 Homo sapiens IL3 gene Proteins 0.000 description 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 101100477531 Homo sapiens SIRPA gene Proteins 0.000 description 1
- 101100519555 Homo sapiens TPO gene Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 101150047851 IL2RG gene Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101150069380 JAK3 gene Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000398750 Muroidea Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100340754 Mus musculus Il3 gene Proteins 0.000 description 1
- 101100477532 Mus musculus Sirpa gene Proteins 0.000 description 1
- 101000694108 Mus musculus Thyroid peroxidase Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 1
- BRMWTNUJHUMWMS-LURJTMIESA-N N(tele)-methyl-L-histidine Chemical compound CN1C=NC(C[C@H](N)C(O)=O)=C1 BRMWTNUJHUMWMS-LURJTMIESA-N 0.000 description 1
- VXOKDLACQICQFA-UHFFFAOYSA-N N-Desethylamiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCNCC)C(I)=C1 VXOKDLACQICQFA-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 241000398990 Nesomyidae Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001338313 Platacanthomyidae Species 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 101100069498 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MGE1 gene Proteins 0.000 description 1
- 101100407739 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PET18 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000288726 Soricidae Species 0.000 description 1
- 241000398956 Spalacidae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001446 anti-myeloma Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002575 chemical warfare agent Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010959 commercial synthesis reaction Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009073 conformational modification Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000024293 detection of nematode Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000526 facies patellaris femoris Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000000604 fetal stem cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 101150047862 hil-6 gene Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 102000044493 human CDCA4 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
- C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722437P | 2012-11-05 | 2012-11-05 | |
| US61/722,437 | 2012-11-05 | ||
| PCT/US2013/068569 WO2014071397A2 (en) | 2012-11-05 | 2013-11-05 | Genetically modified non-human animals and methods of use thereof |
| KR1020227036338A KR102649893B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227036338A Division KR102649893B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20240042142A KR20240042142A (ko) | 2024-04-01 |
| KR102768101B1 true KR102768101B1 (ko) | 2025-02-18 |
Family
ID=49876957
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247008928A Active KR102768101B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
| KR1020227036338A Active KR102649893B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
| KR1020217020816A Active KR102402806B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
| KR1020227017372A Active KR102458016B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
| KR1020157011974A Active KR102275412B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227036338A Active KR102649893B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
| KR1020217020816A Active KR102402806B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
| KR1020227017372A Active KR102458016B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
| KR1020157011974A Active KR102275412B1 (ko) | 2012-11-05 | 2013-11-05 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9901082B2 (enExample) |
| EP (5) | EP2914102B1 (enExample) |
| JP (5) | JP6422441B2 (enExample) |
| KR (5) | KR102768101B1 (enExample) |
| CN (3) | CN104918483B (enExample) |
| AU (3) | AU2013337242B2 (enExample) |
| CA (1) | CA2887706C (enExample) |
| DK (5) | DK4389764T3 (enExample) |
| ES (5) | ES2655442T3 (enExample) |
| FI (2) | FI3939423T3 (enExample) |
| IL (5) | IL311744B2 (enExample) |
| MX (3) | MX377561B (enExample) |
| MY (1) | MY175400A (enExample) |
| NO (1) | NO2946162T3 (enExample) |
| NZ (3) | NZ631614A (enExample) |
| PT (5) | PT2914102T (enExample) |
| RU (1) | RU2673156C2 (enExample) |
| SG (2) | SG10201707449TA (enExample) |
| WO (1) | WO2014071397A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| KR102241962B1 (ko) * | 2012-09-07 | 2021-04-20 | 예일 유니버시티 | 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 |
| DK4389764T3 (da) | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf |
| US9848587B2 (en) | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| HRP20231121T1 (hr) | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| JP6492095B2 (ja) | 2013-10-15 | 2019-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒト化ｉｌ−１５動物 |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| US20150143559A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| RS60398B1 (sr) | 2014-04-08 | 2020-07-31 | Regeneron Pharma | Ne-humane životinje sa humanizovanim fc-gama receptorima |
| BR122023023211A2 (pt) | 2014-04-28 | 2024-01-23 | Recombinetics, Inc. | Método de fazer edições de genes multiplex em uma célula de vertebrado ou de embrião primário não-humano |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| EP3482629B1 (en) * | 2014-05-19 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals expressing human epo |
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| BR112017010793A2 (pt) | 2014-11-24 | 2017-12-26 | Regeneron Pharma | animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo. |
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
| ES2841353T3 (es) | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| WO2016137841A1 (en) * | 2015-02-26 | 2016-09-01 | William Paterson University Of New Jersey | Transgenic mice |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
| ES2950399T3 (es) * | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
| CN108366548B (zh) | 2015-11-20 | 2021-10-08 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| US20190183101A1 (en) * | 2016-08-11 | 2019-06-20 | The Jackson Laboratory | Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| WO2018102546A1 (en) * | 2016-11-30 | 2018-06-07 | The Jackson Laboratory | Humanized mouse model with improved human innate immune cell development |
| SG11201907490XA (en) * | 2017-02-27 | 2019-09-27 | Regeneron Pharma | Non-human animal models of retinoschisis |
| CN107115424B (zh) * | 2017-05-09 | 2018-05-29 | 江西樟树市正康医药生物科技有限公司 | 改变酸性体质保钙及清热解毒的中药组合物及制备方法 |
| US11778994B2 (en) | 2017-05-12 | 2023-10-10 | The Jackson Laboratory | NSG mice lacking MHC class I and class II |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| US11712026B2 (en) | 2017-10-18 | 2023-08-01 | The Jackson Laboratory | Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| WO2019183266A1 (en) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
| IL277355B2 (en) | 2018-03-26 | 2025-01-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| CA3098040A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN111057721B (zh) * | 2018-10-12 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用 |
| CN111172190B (zh) * | 2018-12-25 | 2021-07-30 | 百奥赛图江苏基因生物技术有限公司 | 人源化细胞因子csf2基因改造非人动物的构建方法及应用 |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化凝固因子１２遺伝子座を含む非ヒト動物 |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| WO2021011853A2 (en) * | 2019-07-17 | 2021-01-21 | Yale University | Genetically modified non-human animals and methods of use thereof |
| CN111304246B (zh) * | 2019-12-17 | 2021-05-04 | 百奥赛图江苏基因生物技术有限公司 | 一种人源化细胞因子动物模型、制备方法及应用 |
| EP4087392A4 (en) * | 2020-01-10 | 2024-02-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC MHC PROTEIN COMPLEX |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| AU2021347320A1 (en) | 2020-09-24 | 2023-05-11 | The Jackson Laboratory | Humanized mouse models for assessing immune cell therapy |
| CN116981357A (zh) | 2021-03-31 | 2023-10-31 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| CN116918766A (zh) * | 2022-04-07 | 2023-10-24 | 上海立迪生物技术股份有限公司 | 一种人aml小鼠原位pdox模型的建立方法及应用 |
| CN116918767A (zh) * | 2022-04-07 | 2023-10-24 | 上海立迪生物技术股份有限公司 | 一种人all小鼠原位pdox模型的建立方法及应用 |
| US20240102045A1 (en) | 2022-07-19 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| JP2026522329A (ja) | 2023-06-16 | 2026-07-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ベクター、遺伝子改変細胞、およびそれらを含む遺伝子改変非ヒト動物 |
| WO2025171307A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025250495A1 (en) * | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
| WO2026096736A1 (en) | 2024-10-31 | 2026-05-07 | Regeneron Pharmaceuticals, Inc. | Rodents expressing humanized polymeric immunoglobulin receptor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5573930A (en) | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
| JP2644794B2 (ja) | 1986-10-24 | 1997-08-25 | カイロン コーポレイション | 新規な型のコロニー刺激因子―１ |
| DE3853201T2 (de) | 1987-12-23 | 1995-09-14 | Univ Leland Stanford Junior | Schimäre immunkompromittierende Säugetiere und ihre Verwendung. |
| JP2981486B2 (ja) | 1988-06-14 | 1999-11-22 | メディカル・バイオロジー・インスティチュート | 哺乳動物の免疫系研究方法 |
| JP2935511B2 (ja) * | 1989-10-20 | 1999-08-16 | 忠三 岸本 | ヒトｉｌ―６レセプターの製造方法 |
| US5652373A (en) | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
| US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
| DK0438053T3 (da) | 1990-01-15 | 1999-11-22 | Yeda Res & Dev | Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr |
| JPH04507109A (ja) | 1990-05-03 | 1992-12-10 | システミックス インコーポレイテッド | 免疫無防備状態宿主中におけるヒトリンパ球組織 |
| WO1991018615A1 (en) | 1990-05-25 | 1991-12-12 | Systemix, Inc. | Human peripheral blood cells in an immunocompromised host |
| US5633426A (en) | 1990-05-25 | 1997-05-27 | Systemix, Inc. | In vivo use of human bone marrow for investigation and production |
| EP0571525A1 (en) | 1991-02-11 | 1993-12-01 | OMMAYA, Ayub K. | Spinal fluid driven artificial organ |
| US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
| EP0517199A1 (en) | 1991-06-04 | 1992-12-09 | Yeda Research And Development Company, Ltd. | Durable engraftment of human tissue and cells in normal mammals |
| WO1993005796A1 (en) | 1991-09-19 | 1993-04-01 | The Scripps Research Institute | Method for producing human antibodies in a non-human animal, and animals therefor |
| EP0539970B1 (en) | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
| US6353150B1 (en) | 1991-11-22 | 2002-03-05 | Hsc Research And Development Limited Partnership | Chimeric mammals with human hematopoietic cells |
| WO1993018144A1 (en) | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
| US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
| US6018096A (en) | 1993-05-03 | 2000-01-25 | Surrogen, Inc. | Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells |
| US5663481A (en) | 1993-08-06 | 1997-09-02 | Mount Sinai Hospital Corporation | Animal model of the human immune system |
| CA2195678A1 (en) | 1994-07-27 | 1996-02-08 | Joseph A. Borkowski | Bradykinin b2 receptor modified transgenic non-human animals |
| US6455756B1 (en) | 1994-08-12 | 2002-09-24 | Novartis Ag | Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice |
| US7273753B2 (en) | 1996-08-02 | 2007-09-25 | Center Of Blood Research | Purification and uses of dendritic cells and monocytes |
| US6248721B1 (en) | 1997-04-09 | 2001-06-19 | Lung-Ji Chang | Method of using mouse model for evaluation of HIV vaccines |
| IL132164A0 (en) | 1997-04-09 | 2001-03-19 | Chang Lung Ji | Animal model for evaluation of vaccines |
| GB2337755B (en) * | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| US20030028911A1 (en) | 1999-08-31 | 2003-02-06 | Manley Huang | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| EP1209968A1 (en) | 1999-08-31 | 2002-06-05 | Genencor International, Inc. | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| AU2066301A (en) * | 1999-12-09 | 2001-06-18 | Human Genome Sciences, Inc. | Il-6 like polynucleotide |
| AU2001290855A1 (en) | 2000-09-14 | 2002-03-26 | Genetrol Biotherapeutics, Inc. | Method and cell composition for screening compounds for anti-inflammatory activity |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| BR0211079A (pt) * | 2001-07-10 | 2005-08-30 | Johnson & Johnson Res Pty Ltd | Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas |
| AU2002363322A1 (en) * | 2001-10-26 | 2003-05-19 | Large Scale Biology Corporation | Endothelial cell derived hemotopoietic growth factor |
| JP4087338B2 (ja) | 2001-11-15 | 2008-05-21 | キリンファーマ株式会社 | キメラ非ヒト動物 |
| JPWO2004005496A1 (ja) | 2002-07-05 | 2005-11-04 | 麒麟麦酒株式会社 | 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団 |
| CN101250553A (zh) | 2002-07-13 | 2008-08-27 | 上海医学遗传研究所 | 一种促人血小板生成素表达载体及其构建方法 |
| CA2496233A1 (en) | 2002-09-09 | 2004-03-18 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
| EP1418185A1 (en) | 2002-11-11 | 2004-05-12 | Aventis Pharma Deutschland GmbH | Use of EDG2 receptor in an animal model of heart failure |
| WO2004060053A2 (en) | 2002-12-16 | 2004-07-22 | Genentech, Inc. | Transgenic mice expressing human cd20 |
| CN102225194B (zh) * | 2003-03-12 | 2014-07-16 | 健泰科生物技术公司 | Bv8和/或EG-VEGF促进造血的用途 |
| US20080311095A1 (en) | 2007-05-23 | 2008-12-18 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression |
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
| SI2019683T2 (sl) | 2006-04-25 | 2022-10-28 | The Regents Of The University Of California | Dajanje rastnih faktorjev za zdravljenje motenj CŽS |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| US20080081064A1 (en) | 2006-09-28 | 2008-04-03 | Surmodics, Inc. | Implantable Medical Device with Apertures for Delivery of Bioactive Agents |
| EP2088854A1 (en) | 2006-12-05 | 2009-08-19 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Improved xenogenic immune system in a non-human mammal |
| GB0718029D0 (en) | 2007-09-14 | 2007-10-24 | Iti Scotland Ltd | Two step cluster deletion and humanisation |
| US20110118446A1 (en) | 2007-09-28 | 2011-05-19 | The General Hospital Corporation | Methods and compositions for antibody production |
| WO2009097468A2 (en) | 2008-01-29 | 2009-08-06 | Kliman Gilbert H | Drug delivery devices, kits and methods therefor |
| JP5727458B2 (ja) * | 2009-04-13 | 2015-06-03 | アプセト ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフトＡｐｃｅｔｈ Ｇｍｂｈ ＆ Ｃｏ． Ｋｇ | 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法 |
| SG10201403707QA (en) | 2009-06-29 | 2014-10-30 | Ilya B Leskov | Non-human mammal model of human hematopoietic cancer |
| SG10201403703XA (en) | 2009-06-29 | 2014-10-30 | Qingfeng Chen | Methods of producing humanized non-human mammals |
| RU2425880C2 (ru) | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| EP4502152A3 (en) * | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| EP3498730B1 (en) * | 2009-12-21 | 2026-01-28 | Regeneron Pharmaceuticals, Inc. | Humanized fc gamma r mice |
| WO2012040207A2 (en) * | 2010-09-20 | 2012-03-29 | Yale University | HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE |
| WO2012051572A1 (en) | 2010-10-15 | 2012-04-19 | Massachusetts Institute Of Technology | A humanized non-human mammal model of malaria and uses thereof |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| SI2818478T1 (sl) * | 2011-10-28 | 2017-07-31 | Regeneron Pharmaceuticals, Inc. | Humanizirani il-6 in receptor il-6 |
| KR102241962B1 (ko) | 2012-09-07 | 2021-04-20 | 예일 유니버시티 | 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 |
| DK4389764T3 (da) | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf |
| HRP20231121T1 (hr) | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| JP6492095B2 (ja) | 2013-10-15 | 2019-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒト化ｉｌ−１５動物 |
| EP3482629B1 (en) | 2014-05-19 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals expressing human epo |
| ES2950399T3 (es) | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
-
2013
- 2013-11-05 DK DK24161280.3T patent/DK4389764T3/da active
- 2013-11-05 AU AU2013337242A patent/AU2013337242B2/en active Active
- 2013-11-05 SG SG10201707449TA patent/SG10201707449TA/en unknown
- 2013-11-05 PT PT138116371T patent/PT2914102T/pt unknown
- 2013-11-05 CA CA2887706A patent/CA2887706C/en active Active
- 2013-11-05 EP EP13811637.1A patent/EP2914102B1/en active Active
- 2013-11-05 MX MX2019015882A patent/MX377561B/es active IP Right Grant
- 2013-11-05 NZ NZ631614A patent/NZ631614A/en unknown
- 2013-11-05 SG SG11201502685XA patent/SG11201502685XA/en unknown
- 2013-11-05 ES ES13811637.1T patent/ES2655442T3/es active Active
- 2013-11-05 NZ NZ749626A patent/NZ749626A/en unknown
- 2013-11-05 NZ NZ724353A patent/NZ724353A/en unknown
- 2013-11-05 IL IL311744A patent/IL311744B2/en unknown
- 2013-11-05 KR KR1020247008928A patent/KR102768101B1/ko active Active
- 2013-11-05 KR KR1020227036338A patent/KR102649893B1/ko active Active
- 2013-11-05 CN CN201380056429.6A patent/CN104918483B/zh active Active
- 2013-11-05 MX MX2015005654A patent/MX370856B/es active IP Right Grant
- 2013-11-05 FI FIEP21176673.8T patent/FI3939423T3/fi active
- 2013-11-05 DK DK19176252.5T patent/DK3556206T3/da active
- 2013-11-05 KR KR1020217020816A patent/KR102402806B1/ko active Active
- 2013-11-05 ES ES19176252T patent/ES2884598T3/es active Active
- 2013-11-05 EP EP17184813.8A patent/EP3308641B1/en active Active
- 2013-11-05 CN CN202210388378.8A patent/CN114766432B/zh active Active
- 2013-11-05 ES ES17184813T patent/ES2748662T3/es active Active
- 2013-11-05 PT PT211766738T patent/PT3939423T/pt unknown
- 2013-11-05 FI FIEP24161280.3T patent/FI4389764T3/fi active
- 2013-11-05 IL IL299887A patent/IL299887B2/en unknown
- 2013-11-05 DK DK13811637.1T patent/DK2914102T3/en active
- 2013-11-05 KR KR1020227017372A patent/KR102458016B1/ko active Active
- 2013-11-05 CN CN201810319216.2A patent/CN108401987B/zh active Active
- 2013-11-05 PT PT241612803T patent/PT4389764T/pt unknown
- 2013-11-05 ES ES24161280T patent/ES3069844T3/es active Active
- 2013-11-05 JP JP2015540872A patent/JP6422441B2/ja active Active
- 2013-11-05 KR KR1020157011974A patent/KR102275412B1/ko active Active
- 2013-11-05 RU RU2015121195A patent/RU2673156C2/ru active
- 2013-11-05 US US14/072,626 patent/US9901082B2/en active Active
- 2013-11-05 DK DK21176673.8T patent/DK3939423T3/da active
- 2013-11-05 ES ES21176673T patent/ES2983031T3/es active Active
- 2013-11-05 DK DK17184813.8T patent/DK3308641T3/da active
- 2013-11-05 EP EP21176673.8A patent/EP3939423B1/en active Active
- 2013-11-05 EP EP19176252.5A patent/EP3556206B1/en active Active
- 2013-11-05 EP EP24161280.3A patent/EP4389764B1/en active Active
- 2013-11-05 PT PT171848138T patent/PT3308641T/pt unknown
- 2013-11-05 WO PCT/US2013/068569 patent/WO2014071397A2/en not_active Ceased
- 2013-11-05 PT PT191762525T patent/PT3556206T/pt unknown
- 2013-11-05 MY MYPI2015000877A patent/MY175400A/en unknown
-
2014
- 2014-02-18 NO NO14705284A patent/NO2946162T3/no unknown
-
2015
- 2015-04-27 IL IL238478A patent/IL238478B/en active IP Right Grant
- 2015-05-04 MX MX2020012427A patent/MX2020012427A/es unknown
-
2016
- 2016-06-24 US US15/192,903 patent/US9986724B2/en active Active
-
2017
- 2017-11-06 US US15/804,989 patent/US10785968B2/en active Active
-
2018
- 2018-04-26 IL IL25896818A patent/IL258968B/en active IP Right Grant
- 2018-10-16 JP JP2018194712A patent/JP6772234B2/ja active Active
-
2019
- 2019-07-03 AU AU2019204775A patent/AU2019204775B2/en active Active
- 2019-10-23 IL IL270124A patent/IL270124B2/en unknown
-
2020
- 2020-08-21 US US17/000,140 patent/US11778995B2/en active Active
- 2020-09-30 JP JP2020165884A patent/JP7105844B2/ja active Active
-
2022
- 2022-01-18 AU AU2022200302A patent/AU2022200302B2/en active Active
- 2022-07-12 JP JP2022111649A patent/JP7579304B2/ja active Active
-
2023
- 2023-08-21 US US18/236,218 patent/US20240099278A1/en active Pending
-
2024
- 2024-10-25 JP JP2024187836A patent/JP7877413B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
Non-Patent Citations (4)
| Title |
|---|
| American j. Pathology vol.157 no.5 pp.1485-1493(2000.11.30) |
| J. Exper. Med. vol.185 no.4 pp.755-766(1997.02.17) |
| Proc. Natl. Acad. Sci. USA vol.86 no.19 pp.7547-7551(1989.10.31) |
| Proc. Natl. Acad. Sci. USA vol.92 pp.4862-4866(1995.05.31) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022200302B2 (en) | Genetically modified non-human animals and methods of use thereof | |
| HK40111833A (en) | Genetically modified rodents and methods of use thereof | |
| HK40068456A (en) | Genetically modified non-human animals and methods of use thereof | |
| HK40068456B (en) | Genetically modified non-human animals and methods of use thereof | |
| HK40016315A (en) | Genetically modified non-human animals and methods of use thereof | |
| HK40016315B (en) | Genetically modified non-human animals and methods of use thereof | |
| HK1253909B (en) | Immunodeficient, genetically modified rodent and methods of use thereof | |
| HK1210380B (en) | Genetically modified non-human animals and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0104 | Divisional application for international application | ||
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20240402 Comment text: Request for Examination of Application |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241120 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250211 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250212 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |